Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.
Twitter handle: @jeffmason1
NEW YORK U.S. customers of Rusal are scrambling to figure out how to replace supply from the Russian company after U.S. sanctions on the world's second-largest aluminium producer caused prices to spike to a seven-year high, the companies and metals analysts said.
About 11.8 million consumers nationwide enrolled in 2018 Obamacare exchange plans, a 3 percent drop from last year when 12.2 million consumers signed up, according to a final government tally released on Tuesday by the Centers for Medicare and Medicaid Services.
Valeant Pharmaceuticals , nearly two years into Chief Executive Officer Joseph Papa's turnaround plan, on Wednesday told investors earnings and revenue would drop for one more year, before a projected return to growth in 2019.
NEW YORK New York's attorney general sued the Weinstein Company and Harvey Weinstein on Sunday alleging years of sexual harassment and misconduct by the movie producer, in a move that could jeopardize talks on a potential sale of the studio. | Video
Bristol-Myers Squibb Co on Monday provided some positive data on its immuno-oncology drugs for the most lucrative lung cancer market but it fell short of giving clarity on its ability to compete with a rival treatment from Merck & Co Inc
Lower taxes helped U.S. drugmaker Merck & Co beat analysts' estimate for fourth-quarter earnings on Friday, offsetting weaker-than-expected sales as some of its products face increasing competition.
Eli Lilly and Co posted better than expected fourth-quarter results, but its shares fell 4 percent on Wednesday due to investor concerns about pricing pressure for its diabetes products and weak sales from its animal health unit.
U.S. drugmaker Biogen Inc on Thursday posted better-than-expected fourth-quarter revenue and set upbeat expectations for the year on strong sales from its expensive rare-disease treatment Spinraza.
Healthcare conglomerate Johnson & Johnson on Tuesday took a $13.6-billion charge related to the new U.S. tax law and plans to bring back billions of dollars from overseas immediately.
Celgene Corp will pay $9 billion in cash to buy experimental cancer drugmaker Juno Therapeutics Inc, bulking up its developmental pipeline as it works to reduce reliance on its own cancer treatment Revlimid. | Video
- Gold: PRECIOUS-Gold slips on U.S. rate rise view, easing global tensions
- Oil Report: Armenian PM calls for dialogue with opposition protesters
- British Pound Report: UPDATE 2-Sterling extends slide after Carney punctures BoE rate hike bets
- US Dollar Report: FOREX-Dollar hits 2-week peak on higher U.S. yields; sterling sags